Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
34 hedge funds and large institutions have $169M invested in Sierra Oncology, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 2 closing their positions.
140% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 5
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
13% more capital invested
Capital invested by funds: $150M → $169M (+$19.5M)
3% more funds holding
Funds holding: 33 → 34 (+1)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.81M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$867K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$365K |
| 4 |
BlackRock
New York
|
+$314K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$261K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$269K |
| 2 |
TI
Telemetry Investments
New York
|
-$153K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$136K |
| 4 |
PVI
Pura Vida Investments
New York
|
-$41.7K |
| 5 |
Renaissance Technologies
New York
|
-$23.6K |
SRRA Hedge Fund Activity: Q2 2021 in Review
34 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q2 2021, worth a combined $169M — up 13% from $150M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SRRA positions and 2 closed out — a net gain of 1 holder — while 12 added to existing stakes and 5 trimmed.
The largest buyer was Ikarian Capital, adding an estimated $1.81M. The largest seller was Millennium Management, cutting an estimated $269K.
- 34 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q2 2021, up from 33 in Q1 2021.
- Funds reported $169M of Sierra Oncology, Inc. Common Stock stock for Q2 2021, up 13% quarter-over-quarter.
- 3 funds opened new Sierra Oncology, Inc. Common Stock positions in Q2 2021 and 2 closed out, a net change of +1 holder.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q2 2021 was Ikarian Capital, an estimated $1.81M added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q2 2021 was Millennium Management, an estimated $269K sold.
Based on aggregated 13F filings for Q2 2021.